[177Lu]Lu-PSMA-617
Showing 1 - 25 of 960
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, Best supportive/best standard of care
Not yet recruiting
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- [177Lu]Lu-PSMA-617
- +2 more
- (no location specified)
Jan 2, 2023
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11)
Not yet recruiting
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- [177Lu]Lu-PSMA-617
- +3 more
- (no location specified)
Jan 23, 2023
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial (AAA617, 68Ga-PSMA-11)
Not yet recruiting
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- (no location specified)
Aug 16, 2023
Prostatic Tumors, Castration-Resistant Trial in Darlinghurst, Pretoria (225^Ac-PSMA-617, 68^Ga-PSMA-11)
Recruiting
- Prostatic Neoplasms, Castration-Resistant
- 225^Ac-PSMA-617
- 68^Ga-PSMA-11
-
Darlinghurst, Australia
- +1 more
Nov 23, 2022
Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in San Francisco
Not yet recruiting
- Castrate Resistant Prostate Cancer
- +3 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Mar 1, 2023
Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial (177Lu-PSMA-617, PSMA-11)
No longer available
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- (no location specified)
Jan 12, 2023
Patients With Metastatic Castration-resistant Prostate Cancer Trial (177Lu-PSMA-617 PET scan)
Not yet recruiting
- Patients With Metastatic Castration-resistant Prostate Cancer
- 177Lu-PSMA-617 PET scan
- (no location specified)
Nov 13, 2023
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Seattle
Not yet recruiting
- Castration-Resistant Prostate Carcinoma
- +2 more
- Biopsy
- +9 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Nov 17, 2023
Prostate Cancer Trial in New York (177Lu-PSMA-617, Stereotactic Body Radiotherapy (SBRT))
Active, not recruiting
- Prostate Cancer
- 177Lu-PSMA-617
- Stereotactic Body Radiotherapy (SBRT)
-
New York, New YorkMemorial Sloan Kettering Cancer Center (All Protocol Activities)
Nov 17, 2022
Oligometastatic Prostate Cancer (OMPC) Trial (AAA617)
Not yet recruiting
- Oligometastatic Prostate Cancer (OMPC)
- (no location specified)
Jul 3, 2023
Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Cabozantinib)
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer
-
Salt Lake City, UtahHuntsman Cancer Institute at University of Utah
Nov 10, 2022
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8 Trial in San
Recruiting
- Castration-Resistant Prostate Carcinoma
- +6 more
- Abemaciclib
- Lutetium Lu 177-PSMA-617
-
San Francisco, CaliforniaUniversity of California, San Francisco
Sep 8, 2022
Metastatic Castration-resistant Prostate Cancer, mCRPC Trial in Melbourne (Cabazitaxel, 177Lu-PSMA-617)
Recruiting
- Metastatic Castration-resistant Prostate Cancer
- mCRPC
-
Melbourne, Victoria, AustraliaPeter MacCallum Cancer Centre
Jul 20, 2022
Metastatic Castration-resistant Prostate Cancer Trial in Beijing (1.11GBq of 177Lu-EB-PSMA-617, 2.00 GBq of 177Lu-EB-PSMA-617,
Recruiting
- Metastatic Castration-resistant Prostate Cancer
- 1.11GBq of 177Lu-EB-PSMA-617
- +2 more
-
Beijing, ChinaPeking Union Medical College Hospital
May 6, 2022
Prostate Cancer Trial in Sapporo city, Kanazawa-city (177Lu-PSMA-617, 68Ga-PSMA-11, Best supportive/best standard of care)
Recruiting
- Prostate Cancer
- 177Lu-PSMA-617
- +2 more
-
Kashiwa, Chiba, Japan
- +6 more
Jan 23, 2023
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma Trial in San Francisco
Active, not recruiting
- Castration Levels of Testosterone
- +6 more
- Lutetium Lu 177-PSMA-617
- Pembrolizumab
-
San Francisco, CaliforniaUniversity of California, San Francisco
Apr 11, 2022
Metastatic Hormone Naive Prostate Cancer Trial in Australia (177Lu-PSMA-617, Docetaxel)
Recruiting
- Metastatic Hormone Naive Prostate Cancer
-
Sydney, New South Wales, Australia
- +4 more
Nov 4, 2022
Prostatic Tumors, Castration-Resistant Trial (64Cu-SAR-BBN, 67Cu-SAR-BBN)
Not yet recruiting
- Prostatic Neoplasms
- Castration-Resistant
- (no location specified)
Dec 1, 2022
Renal Cell Carcinoma Trial in Beijing (68Ga-PSMA, 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617)
Recruiting
- Renal Cell Carcinoma
- 68Ga-PSMA
- 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Dec 24, 2021
Prostate Cancer Trial in New Orleans, New York (177Lu-PSMA-617, 68Ga-PSMA-HBED-CC)
Active, not recruiting
- Prostate Cancer
-
New Orleans, Louisiana
- +1 more
Nov 20, 2021
Prostate Cancer Trial in New York (177Lu-PSMA-617, 177Lu-J591, 68Ga-PSMA-HBED-CC)
Terminated
- Prostate Cancer
- 177Lu-PSMA-617
- +2 more
-
New York, New YorkWeill Cornell Medical College
Jul 29, 2021
Prostate Cancer Trial in Vancouver, Montreal, Quebec City (177Lu-PSMA-617, Docetaxel)
Suspended
- Prostate Cancer
-
Vancouver, British Columbia, Canada
- +3 more
Jun 13, 2022
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy
Enrolling by invitation
- Castration-Resistant Prostate Carcinoma
- +2 more
- Computed Tomography
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 16, 2023